Frequently Asked Questions
Here are a few of the primary uses:
Treatment for chronic hepatitis C: It is approved for treating chronic HCV infection in both treatment-nave patients (those who have not previously received HCV treatment) and those who have previously received sofosbuvir without NS5A inhibitors or interferon-based regimens. It works well against all prevalent HCV genotypes.
Liver disease management: It helps in stopping the progression of chronic HCV infection-related liver damage. It can lower the risk of liver cirrhosis, liver failure, hepatocellular cancer, and the requirement for liver transplantation by establishing a persistent virology response, which showed the absence of detectable HCV in the blood six months after completing medication.
High success rates: High cure rates are available; often, they approach 95%. The general health, quality of life, and prognosis of patients can all be enhanced by this outcome.
Effectiveness across all genomes: Its unique formulation makes it possible to treat all of the main HCV genotypes successfully.This makes choosing a course of therapy easier because it eliminates the need for genotype testing, as one drug can treat a variety of HCV genotypes.
Convenience and simplicity: It is a practical treatment choice for patients because it is a once-daily oral pill. Depending on the patient’s characteristics and prior medical history, it has a shorter treatment time than older interferon-based medicines, often lasting 8 to 12 weeks.
- Skin rash
- The length of treatment varies depending on several variables, including the exact HCV genotype and the presence of liver cirrhosis. For most patients, the usual duration of therapy is 12 weeks.
- It frequently has a rapid reduction in HCV levels in the body. There can be noticeable drops in viral load in the first few weeks.
- Even if you see results immediately, finishing the course as directed is crucial. This increases the likelihood of getting a long-lasting virology response. As a result, the virus cannot be found in the blood for at least 12 weeks following the completion of the treatment.